Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Cash & Current Investments: 2020-2024

Historic Cash & Current Investments for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Dec 2024 value amounting to $228.0 million.

  • Arcutis Biotherapeutics' Cash & Current Investments fell 42.20% to $191.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $807.9 million, marking a year-over-year decrease of 40.97%. This contributed to the annual value of $228.0 million for FY2024, which is 16.15% down from last year.
  • As of FY2024, Arcutis Biotherapeutics' Cash & Current Investments stood at $228.0 million, which was down 16.15% from $271.9 million recorded in FY2023.
  • Over the past 5 years, Arcutis Biotherapeutics' Cash & Current Investments peaked at $409.6 million during FY2022, and registered a low of $228.0 million during FY2024.
  • In the last 3 years, Arcutis Biotherapeutics' Cash & Current Investments had a median value of $271.9 million in 2023 and averaged $303.1 million.
  • In the last 5 years, Arcutis Biotherapeutics' Cash & Current Investments soared by 36.08% in 2021 and then plummeted by 33.63% in 2023.
  • Over the past 5 years, Arcutis Biotherapeutics' Cash & Current Investments (Yearly) stood at $284.4 million in 2020, then surged by 36.08% to $387.1 million in 2021, then increased by 5.82% to $409.6 million in 2022, then slumped by 33.63% to $271.9 million in 2023, then decreased by 16.15% to $228.0 million in 2024.